Skip to main content
In stock|Immunotherapy (Investigational Checkpoint)

EOS-448 (Belrestotug)

Oncology TypeSolid Tumour
Drug Class / MechanismTIGIT Inhibitor
No Image
Description

EOS-448 (Belrestotug) is classified as a TIGIT Inhibitor, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational Checkpoint)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3